kleintier konkret, Table of Contents kleintier konkret 2022; 25(06): 16-22DOI: 10.1055/a-1922-2893 Endokrinologie Hund Probleme mit der Cushing-Therapie – Der schlecht einstellbare Patient Christina Lichtenauer , Jennifer von Luckner Recommend Article Abstract Buy Article All articles of this category Die meisten älteren Cushing-Patienten lassen sich gut mit Trilostan einstellen. Doch wie geht man bei den Hunden vor, die nicht wie erwartet auf die Therapie ansprechen? Full Text References Literatur 1 Barker EN, Campbell S, Tebb AJ. et al. A comparison of the survival times of dogs Treated with Mitotane or Trilostane for Pituitary-Dependent Hyperadrenocorticism. J Vet Intern Med 2005; 19: 810-815 2 Reusch CE. Das Cushing-Syndrom beim Hund – Klinik, Diagnose und Therapie. Kleintier konkret 2012; 5: 22-35 3 Foster S, Fleeman LM, Langner KFA. et al. Efficacy and safety of tightly controlled hyperadrenocorticism in dogs treated with trilostane in general practice. J Vet Intern Med 2020; 34: 3058-3166 4 Macfarlane L, Parkin T, Ramsey I. Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs. Vet Rec 2016; 179 (23) 597 5 Arenas C, Melián C, Pérez-Alenza MD. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily. J Vet Intern Med 2013; 27: 1478-1485 6 Kinny-Köster J, von Luckner J. Therapie und Monitoring von Cushing-Patienten – Routine oder Herausforderung?. Kleintier konkret 2021; 24: 46-57 7 Pérez-Alenza D, Melián C. Hyperadrenocorticism in Dogs. In: Ettinger SJ, Feldman EC, Côté E. Textbook of Veterinary Internal Medicine. St. Louis: Elsevier; 2017: 1795-1810 8 Golinelli S, Del Baldo F, Alessandrini F. et al. Evaluation of clinical, ultrasonographic, and clinicopathological findings in dogs with pituitary dependend hypercortisolism and poor trilostane response [Abstract]. ECVIM-CA Online Congress 2021. 9 Wehner A, Glöckner S, Weiss B. et al. Association between ACTH stimulation test results and clinical signs in dogs with hyperadrenocorticism treated with trilostane. Vet J 2021; 276: 105740 10 Bennaim M, Shiel RE, Mooney CT. Diagnosis of spontaneos hyperadrenocorticism in dogs. Part 1: Pathophysiology, aetiology, clinical and clinicopathological features. Vet J 2019; 252: 105342 11 Bennaim M, Shiel RE, Mooney CT. Diagnosis of spontaneos hyperadrenocorticism in dogs. Part 2: Adrenal function testing and differentiating tests. Vet J 2019; 252: 105343 12 Zeugswetter FK, Carranza Valencia A, Glavassevich K. et al. Patterns of the low-dose dexamethasone suppression test in canine hyperadrenocorticism revisited. Vet Clin Path 2021; 50: 62-70 13 Neiger R. Hrsg. Differenzialdiagnosen bei Hund und Katze. 3. Aufl.. Stuttgart: Thieme; 2019 14 Behrend EN, Kooistra HS, Nelson R. et al. Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM Consensus Statement (Small Animal). J Vet Intern Med 2013; 27: 1292-1304 15 Arenas Bermejo C, Pérez Alenza D, García San José P. et al. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2020; 34: 1413-1422 16 Boretti F, Musella C, Burkhardt W. et al. Comparison of two prepill cortisol concentrations in dogs with hypercortisolism treated with trilostane. BMC Vet Res 2018; 14: 417 17 Park SM, Kim KB, Song WJ. et al. Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog. Vet Med Sci 2021; 7: 1150-1153 18 Lee S, Lee A, Chai SH. et al. Ectopic Cushingʼs syndrome associated with a pheochromocytoma in a dog: a case report. BMC Vet Res 2020; 16: 35
